OPK-88004 Reference
Educational, not medical advice reference for OPK-88004: SARM, Hormonal; regulatory status, evidence posture, source review, and schedule notes.…
Plain English
- What it is
- OPK-88004 is a SARM, a lab-made drug that targets the body's muscle-building hormone signals. It is sold only as a research chemical, not as an approved medicine, and no SARM has FDA approval.
- What people use it for
- In bodybuilding and body-recomposition circles it is sometimes talked about for building muscle and losing fat, but that is only anecdotal and is not an approved use. Real-world interest in it is small and stretches far beyond what the research actually tested.
- What the science shows
- It reached a small, short human trial, but the people studied were prostate-cancer survivors, not athletes. In that study it raised lean body mass and lowered body fat, yet it did not improve sexual symptoms or physical performance, and it proved no approved benefit.
- The catch
- The FDA warns the public against SARMs, which are sold illegally and are often mislabeled, and anti-doping rules ban them in sport at all times as anabolic agents (WADA class S1.2). The maker's own testing saw liver enzymes rise in some men. Like other SARMs it can suppress the body's natural testosterone and affect cholesterol and heart health.
Reference summary
A randomized trial in prostate-cancer survivors evaluated sexual symptoms, body composition, and physical function. It did not establish broad clinical benefit or an approved indication.
Regulatory and posture
- Categories
- SARM, Hormonal
- Aliases
- OPK88004, 4-chloro-17α-methyl-andro-4-ene-3β,17β-diol, Steroidal SARM
- Evidence posture
- human - Human trial context was prostate-cancer survivorship, not bodybuilding. Published results do not validate community sexual-function, testosterone-replacement, or performance claims. WADA-prohibited; no FDA approval.
- Regulatory status
- No FDA-approved OPK-88004 drug label. FDA consumer warnings against SARMs sold in bodybuilding products apply to the class. WADA prohibits SARMs under category S1.2 anabolic agents at all times.
- Content review status
- research reference
Selected public sources
- FDA consumer update: SARMs are not FDA-approved and cannot be legally marketed as dietary supplements
- WADA prohibited list: SARMs are category S1.2 anabolic agents prohibited at all times
- PubMed: OPK-88004 randomized trial in prostate cancer survivors
For research and educational purposes only. Not medical advice.